Vericel Corp
VCEL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000887359
In the last 90 days, Vericel Corp insiders filed 0 open-market purchases and 7 sales; 320 institutions reported holding it in 13F filings for Q2 2026, worth $2.47B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $2.48M in total
- 7
- 13F holdersQ2 2026, +43 vs. previous quarter
- 320
- 13F valueReported value at the end of Q2 2026
- $2.47B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding VCEL, Q2 2026
No superinvestor reported holding VCEL at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Vericel Corp insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 14, 2026 (view filing)4:05 PM ET | Aug 12 | 2 days | McLaughlin Kevin FDirector | SSale | −7.00K | $44.53 | −$311.7K | −27.7%18.3K after | 10b5-1 |
| Aug 5, 2026 (view filing)4:05 PM ET | Aug 3 | 2 days | Halpin MichaelChief Operating Officer | SSale | −10.0K | $46.84 | −$468.4K | −37.9%16.4K after | 10b5-1 |
| Jul 31, 2026 (view filing)4:05 PM ET | Jul 30 | 1 day | Siegal JonathanPrincipal Accounting Officer | SSale | −4.50K | $48.90 | −$220.1K | −80.7%1.08K after | 3 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26 | 4 days | Siegal JonathanPrincipal Accounting Officer | SSale | −2.73K | $44.90 | −$122.7K | −75.5%886 after | 2 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26 | 4 days | Mara Joseph Anthony JrChief Financial Officer | SSale | −5.00K | $44.75 | −$223.8K | −23.8%16.0K after | 10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26 | 4 days | Hopper Jonathan MarkChief Medical Officer | SSale | −10.0K | $45.00 | −$450.0K | −11.7%75.8K after | 2 lots10b5-1 |
| Jun 30, 2026 (view filing) | Jun 26 | 4 days | Flynn Sean C.Chief Legal Officer | SSale | −15.0K | $45.64 | −$684.6K | −90.1%1.65K after | 10b5-1 |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Halpin MichaelChief Operating Officer | SSale | −10.0K | $40.24 | −$402.4K | −38.1%16.2K after | 10b5-1 |
| Jun 22, 2026 (view filing) | Jun 18 | 4 days | Flynn Sean C.Chief Legal Officer | SSale | −15.0K | $40.21 | −$603.1K | −90.1%1.65K after | 10b5-1 |
| Jun 4, 2026 (view filing) | Jun 2 | 2 days | Hopper Jonathan MarkChief Medical Officer | SSale | −4.38K | $35.00 | −$153.1K | −5.5%75.8K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Vericel Corp at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,092,226 | $360.0M | 0.01% | +326,882+4.2% | Added |
| State Street Corp | 3,293,975 | $146.6M | 0.00% | +141,845+4.5% | Added |
| Congress Asset Management Co | 2,916,295 | $129.7M | 0.80% | +1,409,377+93.5% | Added |
| Vanguard Capital Management LLC | 2,255,728 | $100.4M | 0.00% | +24,972+1.1% | Added |
| Conestoga Capital Advisors, LLC | 2,083,832 | $92.7M | 2.02% | −379,480−15.4% | Reduced |
| William Blair Investment Management, LLC | 1,992,855 | $88.7M | 0.27% | +160,146+8.7% | Added |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 1,639,988 | $73.0M | 0.07% | −83,584−4.8% | Reduced |
| GW&K Investment Management, LLC | 1,550,497 | $69.0M | 0.54% | −66,358−4.1% | Reduced |
| Soleus Capital Management, L.P. | 1,459,152 | $64.9M | 2.24% | −1,089,927−42.8% | Reduced |
| Geode Capital Management, LLC | 1,341,244 | $59.7M | 0.00% | +86,382+6.9% | Added |